A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer

NCT04676516 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Ottawa Hospital Research Institute

Collaborators